Phoebe Joy Ho

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger et al. · Blood · 2022 · 53 citations

Life Sciences, Immunology, Oncology +16

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

Ross Brown, Andrew Spencer, Phoebe Joy Ho et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 48 citations

Medicine, Hematology, Immunology +15

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>‐19 pandemic

Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman et al. · Internal Medicine Journal · 2020 · 43 citations · Full text

Medicine, Infectious Diseases, Oncology +15

Mass Cytometry Discovers Two Discrete Subsets of CD39−Treg Which Discriminate MGUS From Multiple Myeloma

Felix Marsh‐Wakefield, Annabel Kruzins, Helen M. McGuire et al. · Frontiers in Immunology · 2019 · 27 citations · Full text

Medicine, Hematology, Pathology +15

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Hermann Einsele, J. San‐Miguel, Binod Dhakal et al. · The Lancet Oncology · 2026 · 26 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15